This site is intended only for healthcare professionals resident in the Republic of Ireland




Sign in or RegisterLog out
Our medicinesTherapy areasExplore contentExplore contentMaterialsVideosPodcastsLet’s connectLet's connectContact usSign up



AboutInfliximabWhat is infliximabMechanism of actionBiosimilarsApprovalOverviewPosition statementsECCOEULARESPGHANDosing & SwitchingDosingIV dosingAdministration & storageIV administrationStorageSafety informationImportant safety informationSwitchingConsiderations for switchingSafety informationImportant safety informationSafety informationImportant safety informationClinical EvidenceRandomised controlled trial evidenceSummary: randomised controlled trial evidenceSupport & ResourcesMaterials
Summary: randomised controlled trial evidenceClinical confidence of INFLECTRA® (CT-P13*/infliximab) includes randomised controlled trials1-8INFLECTRA® infusion therapy (CT-P13*) has been evaluated across 5 randomised controlled trials1-8
CT-P13 is marketed under different brand names including INFLECTRA® and REMSIMA™.Remicade™ is a registered trademark of MSD.AS, Ankylosing spondylitis; CD, Crohn’s disease; IV, Intravenous; PsA, Psoriatic arthritis; PsO, Psoriasis; RA, Rheumatoid arthritis; RCT, Randomised controlled trial; SC, subcutaneous; SpA, Spondyloarthritis; UC, Ulcerative colitis.

Please refer to the INFLECTRA® Summary of Product Characteristics for full prescribing information

References:Yoo DH, et al. Ann Rheum Dis 2013;72:1613-20. Yoo DH, et al. Ann Rheum Dis 2017;76:355-63.Park W, et al. Ann Rheum Dis 2013;72:1605-12. Park W, et al. Ann Rheum Dis 2017;76:346-54.Byong Duk Y, et al. Lancet 2019;393:1699-707. Jørgensen KK, et al. Lancet 2017;389:2304-16.Goll GL, et al. J Intern Med 2019;285(6):653-69. Takeuchi T, et al. Mod Rheumatol 2015;25:817-24. NCT02096861. Available at: NCT02096861?term=CT-P13&rank=1
Safety information

Review important information about the safety and tolerability of INFLECTRA®

Learn more Loading

Legal Category: S1A
Further information is available upon request

PP-IFA-IRL-0149 May 2023

Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)

Adverse events should also be reported to Pfizer Medical Information on 1800 633 363

PfizerPro AccountPfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Sign in or RegisterRegisterAccountLog out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit


This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.


Copyright © 2023 Pfizer Limited. All rights reserved.

PP-UNP-IRL-0176. January 2023
For Healthcare Professionals in the Republic of Ireland *

The information contained on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland.

I confirm that I am a healthcare professional resident in the Republic of Ireland.*

I accept and agree to the terms of use.*

If you select 'No', you will be redirected to, where you will be able to access information on Pfizer Healthcare Ireland.

PP-UNP-IRL-0176. January 2023

Yes No
You are now leaving PfizerPro
You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.